The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU ...

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...

AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo.

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...

T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in ...

Caring for someone with metastatic breast cancer can be demanding physically, emotionally, and financially, but there are ...

Fatigue is a very common symptom of metastatic breast cancer, and it can significantly impact quality of life. Here are ways ...

An MP diagnosed with breast cancer for a second time wants to "debunk" misconceptions about metastatic cancers. Labour MP for ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

In the next step, the researchers want to develop new molecules based on digoxin that are even better at dissolving the CTC clusters.

Successful test in breast cancer patients: the active agent digoxin, a cardiac medication, dissolves clusters of circulating breast cancer cells in the blood, thus reducing the risk of metastases ...

Virginia G. Kaklamani, MD, DSc, discusses datopotamab deruxtecan and other antibody-drug conjugates available for patients with unresectable or metastatic hormone receptor-positive, HER2-negative ...